Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FLKS

Flex Pharma (FLKS) Stock Price, News & Analysis

Flex Pharma logo

About Flex Pharma Stock (NASDAQ:FLKS)

Advanced Chart

Key Stats

Today's Range
$0.75
$0.87
50-Day Range
$0.57
$14.51
52-Week Range
$0.26
$1.49
Volume
92,971 shs
Average Volume
2.03 million shs
Market Capitalization
$14.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FLKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flex Pharma and its competitors with MarketBeat's FREE daily newsletter.

FLKS Stock News Headlines

FLEX LNG: A Bond-Like 11.9% Yield To Lock Before Rate Cuts
FLEX LNG Ltd. (FLNG) Q2 2024 Earnings Call Transcript
Thirty-Year “Wonder Material” Finally Ready for Factory Floors
A Nobel-recognized material once trapped in research labs is finally ready for the real world. After a 90% cost breakthrough, this wonder-material is being tested by aerospace giants, battery developers, and chip makers alike. Now, a new briefing reveals the companies best positioned to profit from its mass adoption.
Wayfair Inc. (W) Q2 2024 Earnings Call Transcript
Q2 2024 AGCO Corp Earnings Call
Flex Ltd. (FLEX) Q1 2025 Earnings Call Transcript
Flex Ltd.: Undervalued With Solid Fundamentals
See More Headlines

FLKS Stock Analysis - Frequently Asked Questions

Flex Pharma Inc (NASDAQ:FLKS) announced its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported ($0.12) earnings per share for the quarter. The biotechnology company had revenue of $0.11 million for the quarter. Flex Pharma had a negative net margin of 1,208.42% and a negative trailing twelve-month return on equity of 98.04%.

Flex Pharma (FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Flex Pharma investors own include Micron Technology (MU), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Gilead Sciences (GILD) and Histogenics (HSGX).

Company Calendar

Last Earnings
5/01/2019
Today
7/07/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FLKS
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.92 million
Net Margins
-1,208.42%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$840 thousand
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
1.74

Miscellaneous

Free Float
N/A
Market Cap
$16.05 million
Optionable
Not Optionable
Beta
1.65
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:FLKS) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners